查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869948

僵直性脊椎炎市場規模、佔有率和趨勢分析報告：按藥物類別、分銷管道、地區和細分市場預測（2025-2033 年）

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (NSAID, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

僵直性脊椎炎市場摘要

2024年全球僵直性脊椎炎市場規模估計為62.9億美元，預計2033年將達到110.8億美元。

預計從 2025 年到 2033 年，該市場將以 6.4% 的複合年成長率成長。推動市場成長的因素包括發炎性疾病盛行率的上升以及醫療保健提供者診斷意識的提高。

由於發炎性疾病盛行率不斷上升以及醫療保健提供者診斷意識的增強，市場持續成長。僵直性脊椎炎 (AS)相關的慢性下背痛可藉助磁振造影 (MRI) 和電腦電腦斷層掃描)等先進影像技術在早期階段得到準確診斷，從而增加了對早期療育的需求。這有助於加快治療啟動並改善長期療效，進而推動標靶治療的應用。例如，根據《美國管理式醫療雜誌》(American Journal of Managed Care) 2024 年 9 月的一份報告，美國食品藥物管理局(FDA) 已批准 bimekizumab-bkzx (Bimzelx) 用於治療成人僵直性脊椎炎(AS)、非關節炎性中軸型脊椎乾癬性關節炎(Pax-A)。這核准首個核准用於這些適應症的 IL-17A 和 IL-17F 雙重抑制劑。基於 III 期 BE MOBILE 試驗的結果，這項里程碑式的核准擴大了治療選擇範圍，並加強了市場成長。

生物製藥的進步也是推動市場成長的主要因素。標靶腫瘤壞死因子 (TNF) 和白細胞介素-17 (IL-17) 路徑的生物製藥徹底改變了僵直性脊椎炎的治療。這些治療方法因其能夠減輕發炎、延緩疾病進展並改善生活品質，而成為醫生和患者的首選。例如，UCB 在 2023 年 11 月舉行的 ACR Convergence 2023 大會上宣布，BIMZELX（bimekizumab）在五年內持續改善了疾病活動度、身體功能和生活品質，且安全性良好。在開放標籤擴展研究 (OLE) 中入組的 303 名患者中，有 202 名患者持續接受治療至第 256 週，ASAS40 緩解率維持在約 50%。生物相似藥的推出有望提高治療的可近性和成本效益，從而進一步擴大治療應用範圍。製藥公司正積極投資臨床研究，以開發新型生物製藥和小分子療法。增加新藥認證，可以提供病人和醫生更多選擇。

對個人化醫療的日益重視正在塑造市場未來的機會。基因檢測和基於生物標記的方法能夠更精準地選擇適合個別患者的治療方法。這些方法提高了治療效果，並降低了副作用的風險。數位健康平台和遠端醫療的擴展正在改善患者監測，並提高患者對長期治療方案的依從性。製藥公司和研究機構之間日益密切的合作正在加速創新治療方法的研發。僵直性脊椎炎造成的全球性殘疾負擔也推動了對先進治療方法的需求，以恢復患者的活動能力並減輕疼痛。預計這些趨勢將在未來幾年內持續推動市場成長。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章僵直性脊椎炎市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章僵直性脊椎炎市場：藥物類別業務分析

  • 2024 年及 2033 年各藥物類別市佔率
  • 藥物類別細分儀表板
  • 按藥物類別分類的市場規模、預測和趨勢分析，2021-2033年
  • 非類固醇消炎劑（NSAIDs）
  • TNF抑制劑
  • 其他藥物類別

第5章僵直性脊椎炎市場：通路的業務分析

  • 2024 年及 2033 年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析，2021-2033年
  • 醫院藥房
  • 零售藥房
  • 其他

第6章僵直性脊椎炎市場：區域估算與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 按國家/地區分類，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • AbbiVie, Inc.
    • Amgen, Inc.
    • Pfizer, Inc.
    • Johnson &Johnson, Inc.
    • Novartis AG
    • UCB, Inc.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Zydus Lifescience Ltd.
    • Izana Bioscience
Product Code: GVR-4-68038-728-5

Ankylosing Spondylitis Market Summary

The global ankylosing spondylitis market size was estimated at USD 6.29 billion in 2024 and is projected to reach USD 11.08 billion by 2033, growing at a CAGR of 6.4% from 2025 to 2033. The market is growing due to the rising prevalence of inflammatory diseases and greater diagnostic awareness among healthcare providers.

The market is growing due to the rising prevalence of inflammatory diseases and greater diagnostic awareness among healthcare providers. Chronic back pain associated with ankylosing spondylitis is increasing demand for early intervention, supported by advanced imaging techniques such as MRI and CT scans that enable accurate diagnosis at earlier stages. This accelerates treatment initiation and improves long-term outcomes, driving adoption of targeted therapies. For instance, in September 2024, the American Journal of Managed Care reported that the FDA had approved bimekizumab-bkzx (Bimzelx) for adults with AS, nr-axSpA, and PsA, marking the first dual IL-17A and IL-17F inhibitor to secure approval for these indications. Supported by Phase 3 BE MOBILE trials, this milestone expanded therapeutic options and strengthened market growth.

Advancements in biologic therapies are another major factor contributing to market growth. Biologic agents targeting tumor necrosis factor (TNF) and interleukin-17 (IL-17) pathways have transformed the management of ankylosing spondylitis. These therapies reduce inflammation, slow disease progression, and improve quality of life, making them the preferred choice among physicians and patients. For instance, in November 2023, UCB reported at ACR Convergence 2023 that BIMZELX (bimekizumab) delivered sustained five-year improvements in ankylosing spondylitis across disease activity, physical function, and quality of life, with consistent safety. Among 303 patients entering OLE, 202 remained at Week 256, with ASAS40 response rates maintained near 50%. The introduction of biosimilars is also increasing accessibility and affordability, which further expands treatment adoption rates. Pharmaceutical companies actively invest in clinical research to develop novel biologics and small-molecule therapies. Regulatory bodies ' increasing approvals of new drugs give patients and physicians more options.

The rising focus on personalized medicine shapes future opportunities in the market. Genetic testing and biomarker-driven approaches enable more precise selection of therapies tailored to individual patient needs. Such approaches enhance treatment effectiveness and reduce the risk of adverse reactions. The expansion of digital health platforms and telemedicine is improving patient monitoring and adherence to long-term treatment plans. Growing collaborations between pharmaceutical companies and research institutes lead to faster development of innovative treatment options. The global burden of disability linked with ankylosing spondylitis is also pushing demand for advanced therapies that restore mobility and reduce pain. These trends are expected to sustain market growth over the coming years.

Global Ankylosing Spondylitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ankylosing spondylitis market report based on drug class, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-Steroidal Anti-Inflammatory Drug (NSAID)
  • TNF Inhibitors
    • Humira
    • Simponi
    • Remicade
    • Enbrel
    • Cimzia
    • Other TNF Inhibitors
  • Other Drug Classes
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Distribution channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Ankylosing Spondylitis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Ankylosing Spondylitis Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.4. Non-Steroidal Anti-Inflammatory Drug (NSAID)
    • 4.4.1. Non-Steroidal Anti-Inflammatory Drug (NSAID) Market, 2021 - 2033 (USD Million)
  • 4.5. TNF Inhibitors
    • 4.5.1. TNF Inhibitors Market, 2021 - 2033 (USD Million)
    • 4.5.2. Humira
      • 4.5.2.1. Humira Market, 2021 - 2033 (USD Million)
    • 4.5.3. Simponi
      • 4.5.3.1. Simponi Market, 2021 - 2033 (USD Million)
    • 4.5.4. Remicade
      • 4.5.4.1. Remicade Market, 2021 - 2033 (USD Million)
    • 4.5.5. Enbrel
      • 4.5.5.1. Enbrel Market, 2021 - 2033 (USD Million)
    • 4.5.6. Cimzia
      • 4.5.6.1. Cimzia Market, 2021 - 2033 (USD Million)
    • 4.5.7. Other TNF Inhibitors
      • 4.5.7.1. Other TNF Inhibitors Market, 2021 - 2033 (USD Million)
  • 4.6. Other Drug Classes
    • 4.6.1. Other Drug Classes Market, 2021 - 2033 (USD Million)

Chapter 5. Ankylosing Spondylitis Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacy
    • 5.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacy
    • 5.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Ankylosing Spondylitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbiVie, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Pfizer, Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Johnson & Johnson, Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Novartis AG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. UCB, Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Eli Lilly and Company
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Zydus Lifescience Ltd.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Izana Bioscience
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global ankylosing spondylitis market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 5. Global ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 8. North America ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 10. U.S. ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 12. Canada ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 14. Mexico ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 17. Europe ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 19. UK ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 21. Germany ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 23. France ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 25. Italy ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 27. Spain ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 29. Norway ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 31. Denmark ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 33. Sweden ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD
  • Table 37. Japan ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 38. Japan ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 40. China ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 42. India ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 44. Australia ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 46. South Korea ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 48. Thailand ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 51. Latin America ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 53. Brazil ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 55. Argentina ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 60. South Africa ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 64. UAE ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
  • Table 66. Kuwait ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Ankylosing spondylitis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and drug class outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Ankylosing spondylitis market dynamics
  • Fig. 12 Ankylosing spondylitis market: Porter's five forces analysis
  • Fig. 13 Ankylosing spondylitis market: PESTLE analysis
  • Fig. 14 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 15 Non-Steroidal Anti-Inflammatory Drug (NSAID) market, 2021 - 2033 (USD Million)
  • Fig. 16 TNF Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 17 Humira market, 2021 - 2033 (USD Million)
  • Fig. 18 Simponi market, 2021 - 2033 (USD Million)
  • Fig. 19 Remicade market, 2021 - 2033 (USD Million)
  • Fig. 20 Enbrel market, 2021 - 2033 (USD Million)
  • Fig. 21 Cimzia market, 2021 - 2033 (USD Million)
  • Fig. 22 Other TNF Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 23 Other Drug Classes market, 2021 - 2033 (USD Million)
  • Fig. 24 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 25 Hospital Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 26 Retail Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Ankylosing spondylitis market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait ankylosing spondylitis market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework